Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

You must log in to access content on this page. Or click here to request access.
MediBeacon Inc. Appoints Dr. Steve Miller as Chief Medical Officer

MediBeacon expands management team as enrollment in Phase 3 study focused on kidney disease is completed

ST. LOUIS, May 16, 2023 - MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of
INNOVATE Corp. (NYSE: VATE), today announced the appointment of Dr. Steve Miller as chief medical officer. In this
role, Dr. Miller will be focused on driving a range of clinical and strategic initiatives.
Dr. Miller formerly served as executive vice president and chief clinical officer at Cigna, where he led the
company’s clinical policy, quality, and performance efforts. Dr. Miller was chief medical officer at Express Scripts in
advance of Cigna’s acquisition of the company. Prior to Express Scripts Dr. Miller was vice president and chief medical
officer at Barnes-Jewish Hospital, Washington University School of Medicine in St. Louis. He has been a member of the
MediBeacon board of directors since 2015.

“We are thrilled to have Dr. Miller take on a more active role at MediBeacon,” said Steve Hanley, chief executive officer,
MediBeacon. “Dr. Miller has a strong understanding of the MediBeacon kidney monitoring technology as it applies to a
range of unmet medical needs. His intimate knowledge of the company, combined with his business, healthcare policy,
medical, clinical and research experience provides unique and valuable perspective.”
MediBeacon is a medical technology company focused on advancing fluorescent technology to help improve patient
care through the science of tracer agents and transdermal measurement.

“Understanding kidney function remains a significant clinical challenge,“ said Dr. Miller. “Real-time, accurate renal
function measurements have the potential to have meaningful impact in patient management. MediBeacon’s goal
continues to be to provide technology to aid in both improving health outcomes and reducing costs of kidney disease.”
Dr. Miller received his medical degree from the University of Missouri-Kansas City and completed an internal medicine
residency at the University of Colorado. He trained as a fellow in pathology and research at the University of Alabama,
Birmingham; nephrology at Washington University; and did a cardiology research fellowship at University of California,
San Francisco. Dr. Miller earned an MBA at the Washington University Olin Business School.

The MediBeacon® Transdermal GFR Measurement System (TGFR) is designed to measure Glomerular Filtration Rate
(GFR), an indicator of kidney function, in real-time without the need for blood sampling or urine collection. The TGFR
was designated a Breakthrough Device by the U.S. FDA and an Innovative Medical Device by China NMPA.
MediBeacon Inc. 425 N. New Ballas Road, Suite 100 St. Louis, MO 63141

Download PDF

MediBeacon TGFR Pivotal Study
MediBeacon TGFR Pivotal Study (NCT05425719) is a Phase 3 open label, multi-center, safety and pharmacokinetic
study of Lumitrace® (relmapirazin) and the use of the MediBeacon Transdermal GFR Measurement System (TGFR) in
normal and renal compromised subjects for the evaluation of kidney function. The safety and effectiveness of the
MediBeacon TGFR for point of care non-invasive transdermal fluorescence detection of Lumitrace is being evaluated in
subjects with kidney function from normal to Stage 4 CKD. Patient enrollment covers the entire range of human skin
colors spanning fair to black pigmentation. The study's primary outcome measure is the correlation of Transdermal
Derived Glomerular Filtration Rate (tGFR) to the Measured GFR (mGFR) obtained from blood samples collected over

About Lumitrace® (relmapirazin)
Lumitrace is an investigational pyrazine-based compound which has been engineered to be inert, highly fluorescent and
have the clearance properties of a GFR tracer agent in the body. The investigational Lumitrace solution for injection has
been administered to over 500 subjects under Investigational Device Exemptions (IDEs). The unique photophysical
characteristics of Lumitrace have been designed to enable the collection of fluorescence data via a photodetector sensor
placed on the skin. Data collected by the sensor measures the change in the intensity of Lumitrace fluorescence over
time and is converted into a tGFR by proprietary algorithms.

About MediBeacon Inc.
MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and
transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection
technology focuses on providing vital and actionable measurement of organ function. MediBeacon’s 47 granted U.S.
patents and 170+ granted patents worldwide provide extensive coverage of the MediBeacon TGFR, including Lumitrace,
the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology
including potential applications in nephrology, gastroenterology, ophthalmology and surgery. MediBeacon products are
in various stages of clinical development and are NOT yet approved for human use. For more information, please visit:

About INNOVATE Corp.
INNOVATE Corp. is a portfolio of best-in-class assets in three key areas of the new economy – Infrastructure, Life
Sciences and Spectrum. Dedicated to stakeholder capitalism, INNOVATE employs approximately 3,900 people across
its subsidiaries. For more information, please visit: